-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Changing the Path of Myelofibrosis: Envisioning a Brighter Future for Our Patients

Sponsor: Morphosys
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Diseases, Therapies, Adverse Events
Friday, December 8, 2023: 3:00 PM-6:00 PM
Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)
John Mascarenhas, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Mascarenhas: Bristol Myers Squibb, Celgene, CTI BioPharma, Geron, Incyte Corporation, Janssen, Kartos Therapeutics, Merck, Novartis, PharmaEssentia, Roche; Participated in consulting or advisory committees – AbbVie, Bristol Myers Squibb, Celgene, Constellation Pharmac: Research Funding; Incyte, Novartis, Roche, Geron, GSK, Celgene/BMS, Kartos, AbbVie, Karyopharm, PharmaEssentia, Galecto, Imago, Sierra Oncology, Pfizer, MorphoSys, CTI Bio: Consultancy; Bristol Myers Squibb, Celgene, Constellation Pharmaceuticals/MorphoSys, CTI BioPharma, Galecto, Geron, GSK, Incyte Corporation, Karyopharm Therapeutics, Novartis, PharmaEssentia, Prelude Therapeutics, Pfizer, Merck, Roche, AbbVie, Kartos: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie, Bristol Myers Squibb, Celgene, CTI BioPharma, Geron, Incyte Corporation, Novartis, Janssen, Kartos Therapeutics, Merck, PharmaEssentia, Roche: Research Funding; AbbVie, CTI BioPharma Corp, a Sobi company, Geron, GlaxoSmithKline, Imago, Incyte, Kartos, Kayropharm, MorphoSys, Novartis, Pfizer, PharmaEssentia, Sierra: Consultancy; GSK: Honoraria.
Ann Mullally, MD, Dana-Farber Cancer Institute , Ronald Hoffman, MD, Tisch Cancer Institute and Claire N Harrison, Guy’s and St. Thomas’ NHS Foundation Trust
Mullally: Relay, Morphic: Research Funding; PharmaEssentia, Incyte: Other: Steering Committee ; AOP Health: Speakers Bureau; Constellation, Protagonist: Other: Advisory Board ; Aclaris, Cellarity, Morphic, Biomarin: Consultancy. Hoffman: Dompe: Patents & Royalties; Dexcel Pharma: Research Funding; Karyopharm: Research Funding; Summitomo: Research Funding; Kartos Abbvie: Research Funding; Silence Therapeutics: Consultancy; TD2: Research Funding; Curis: Research Funding; Cellinkos: Consultancy; Protagonist Therapeutics: Consultancy. Harrison: AOP: Honoraria, Speakers Bureau; GSK: Honoraria, Speakers Bureau; Abbvie: Honoraria, Speakers Bureau; CTI: Honoraria, Speakers Bureau; Galecto: Honoraria, Speakers Bureau; Morphosys: Honoraria, Speakers Bureau; Novartis: Honoraria, Research Funding, Speakers Bureau; BMS: Honoraria, Speakers Bureau.
On Demand program will be available here January 8, 2024.

Myelofibrosis (MF) is a rare disease that has a significant impact on patient’s quality of life. While many remain symptom-free for years, ultimately symptoms impose a major burden. While Janus kinase (JAK) inhibitors play an important role in treating MF, a variety of novel targeted therapies are in clinical development that have the potential to prevent/delay resistance to ruxolitinib, change the course of the disease, and advance patient outcomes. This interactive symposium will start by providing an overview of the challenges associated with current management from a physician’s perspective followed by an interview with a patient with MF to highlight the challenges that they face. We then continue with a deeper dive into the biological path of MF, how to target the stem cell and microenvironment in MF, the path of epigenetic dysregulation fueling the development of epigenetic therapies, as well as other emerging therapies in Myeloproliferative neoplasms. The session will end with a group discussion reviewing how these new developments may positively impact the evolving journey of patients with MF.